The wide - moat pharmacy benefit manager is still undervalued.
We expect strong top-line growth but, in the near term, contracting margins for the wide - moat e-commerce firm.
Forget about minimizing risk. Instead, make sure that you are adequately compensated for the risks you're taking on, says Morningstar's Matt Coffina.
Why this week's GDP wasn't quite as good as it looked. Plus: Hawkish hints from the Fed and earnings hits and misses.
We’re lowering our fair value estimate for the Internet giant after a disappointing third quarter, but we still see shares as undervalued and the firm as a disruptive force.
Shares are still overvalued today, but dramatic expense growth could spook short-term oriented investors and create a compelling entry point in this wide - moat social network, says Morningstar’s Rick Summer
Morningstar's Todd Wenning takes a look back at the small-cap stocks featured over the past year.
Despite shutting down half of its brand portfolio, wide - moat Procter & Gamble should maintain its scale advantages and increase shareholders' total return through dividend payments.
Investors have started to pay attention to risk again, but market valuations overall don't offer much margin of safety, says Morningstar's Matt Coffina.
Morningstar's Josh Peters sizes up the disappointing results from McDonald's and Coke, and GE's nice surprise.